Equities analysts expect Marrone Bio Innovations Inc (NASDAQ:MBII) to post $9.01 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Marrone Bio Innovations’ earnings, with the highest sales estimate coming in at $10.10 million and the lowest estimate coming in at $7.92 million. Marrone Bio Innovations posted sales of $5.75 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 56.7%. The firm is scheduled to issue its next earnings report on Tuesday, August 13th.

On average, analysts expect that Marrone Bio Innovations will report full year sales of $31.66 million for the current year, with estimates ranging from $27.00 million to $36.52 million. For the next financial year, analysts anticipate that the company will post sales of $40.70 million, with estimates ranging from $34.00 million to $46.77 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Marrone Bio Innovations.

Marrone Bio Innovations (NASDAQ:MBII) last issued its earnings results on Thursday, May 9th. The basic materials company reported ($0.04) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). Marrone Bio Innovations had a negative net margin of 82.82% and a negative return on equity of 123.95%. The firm had revenue of $8.72 million during the quarter, compared to analysts’ expectations of $6.18 million.

Separately, National Securities reissued a “buy” rating and set a $10.00 target price on shares of Aqua Metals in a report on Friday, May 10th.

Shares of Marrone Bio Innovations stock traded up $0.01 during trading on Friday, hitting $1.42. 45,999 shares of the company’s stock were exchanged, compared to its average volume of 79,893. The company has a quick ratio of 1.47, a current ratio of 1.94 and a debt-to-equity ratio of 2.47. The firm’s 50-day simple moving average is $1.47. Marrone Bio Innovations has a 52-week low of $1.10 and a 52-week high of $2.18. The company has a market cap of $157.23 million, a PE ratio of -6.76 and a beta of -0.08.

Institutional investors have recently modified their holdings of the stock. Paloma Partners Management Co acquired a new stake in Marrone Bio Innovations during the fourth quarter valued at $73,000. SG Americas Securities LLC acquired a new stake in Marrone Bio Innovations during the first quarter valued at $74,000. Spark Investment Management LLC grew its position in Marrone Bio Innovations by 47.5% during the first quarter. Spark Investment Management LLC now owns 95,000 shares of the basic materials company’s stock valued at $145,000 after buying an additional 30,600 shares during the period. Geode Capital Management LLC grew its position in Marrone Bio Innovations by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 443,611 shares of the basic materials company’s stock valued at $652,000 after buying an additional 24,460 shares during the period. Finally, Rhumbline Advisers grew its position in Marrone Bio Innovations by 44.3% during the fourth quarter. Rhumbline Advisers now owns 68,021 shares of the basic materials company’s stock valued at $100,000 after buying an additional 20,882 shares during the period. 42.04% of the stock is owned by hedge funds and other institutional investors.

About Marrone Bio Innovations

Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.

See Also: Trade War

Get a free copy of the Zacks research report on Marrone Bio Innovations (MBII)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Marrone Bio Innovations (NASDAQ:MBII)

Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.